Improvement in overall disease activity A greater proportion of patients attained a BICLA response in the anifrolumab group compared with the placebo group from Week 8 (second assessment, nominal p<0.001); this nominally significant treatment difference was seen in all subsequent visits through to Week 52 ( figure 1A ).
← all excerpts
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
1
—
—